Physician profile
Gerald R Schultz
NPI 1942293543
$2,381.92
in general payments reported to CMS, 2019-2025
15 companies · $560 in 2025
The $560 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $263 · 2021: $121 · 2022: $60.00 · 2023: $354 · 2024: $281 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,195.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $669.89 | 2019-2020 | |
| Amgen INC. | $542.54 | 2025 | Tepezza |
| Alcon Vision LLC | $226.79 | 2019-2024 | Hydrus Microstent |
| Bausch & Lomb Americas INC. | $199.67 | 2023-2024 | Infuse |
| Ocular Therapeutix, INC. | $148.30 | 2023 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $137.92 | 2024 | Tecnis Iol |
| Dompe US, INC. | $120.69 | 2021 | |
| Medtronic Vascular, INC. | $100.42 | 2020 | |
| Allergan, INC. | $79.90 | 2020 | |
| Carl Zeiss Meditec, INC. | $60.00 | 2022 | |
| Abbvie INC. | $34.21 | 2024 | |
| Astellas Pharma US INC | $21.16 | 2023 | Izervay |
| Horizon Therapeutics Plc | $20.37 | 2023 | Tepezza |
| Boston Scientific Corporation | $17.57 | 2025 | Wavewriter Alpha Prime 16 |
| Travere Therapeutics, INC. | $2.49 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.